Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Minimum life expectancy of ≥ 12 weeks.
Have a recurrent advanced or metastatic solid tumor that is histologically or cytologically confirmed.
Adequate organ and marrow function.
Not amenable to curative treatment with surgery or radiation.
Received at least 1 line of prior systemic anticancer therapy in the recurrent or metastatic setting.
Acceptable alternative therapy was received, refused, intolerable, or no longer effective.
Capable of understanding and complying with the protocol requirements and provide signed informed consent according to the protocol and local requirements.
You may not be if
Primary brain tumors or known active brain metastases.
Major surgery (eg, gastrointestinal surgery, removal or biopsy of brain metastasis) within 4 weeks before the first dose of study treatment.
Received radiation therapy within 1 week before the first dose of study treatment or clinically relevant ongoing complications from prior radiation therapy.
Received prior therapy targeting NK cells (eg, monalizumab).
A woman of childbearing potential has a positive serum pregnancy test within 7 days prior to study treatment.
